Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY

Put It on the Board

December 2020—Antimicrobial Susceptibility Testing: Monitoring and Trend Analysis is a new CAP program that is beginning to roll out to laboratories this month. The CDC guidance for antibiotic stewardship consists of seven core elements to address resistance-associated risks, one of which points to the importance of laboratory collaboration, communication, and AST reporting practices to the success of stewardship programs. According to this core element, the laboratory must provide information to guide discussions on the potential implementation of test interpretive criteria, such as changes in antibiotic breakpoints, that might affect antibiotic use.

Magnolia launches Mission to Zero

November 2020—Magnolia Medical Technologies launched Mission to Zero to bring greater awareness to patient safety and antibiotic-associated risks caused by false-positive diagnostic test results for sepsis. Magnolia is launching the initiative by partnering with emergency departments, critical care units, clinical laboratories, and infection prevention teams within acute care hospitals. Each team member makes an individual pledge to participate, the company says, which allows all departments to work in tandem to ensure the best possible patient outcomes and experience are achieved.

Thermo Fisher introduces hematology-oncology portfolio

November 2020—Thermo Fisher Scientific announced the availability of its Oncomine Myeloid Assay GX, the first in a series of clinical research assays available from the company’s new portfolio of hematology-oncology assays for the Ion Torrent Genexus System.

Bionano Prep SP Tissue and Tumor Kit

N0vember 2020—Bionano Genomics has launched the Bionano Prep SP Tissue and Tumor Kit, a DNA isolation kit developed for analysis of tumors and tissue with the company’s Saphyr system. The kit has been designed to simplify isolation of ultra-high-molecular-weight DNA from a variety of solid tumors and tissue types.

Alpha-Tec QC1 malaria slides

November 2020—Alpha-Tec Systems has released quality control slides containing smears of red blood cells infected with a mixture of ring-form, trophozoite, and schizont stages of Plasmodium falciparum. The slides are prefixed with methanol and are ready to stain with traditional Giemsa, Wright’s, or Field stains.

Cepheid SARS-CoV-2, flu, RSV test gets EUA

November 2020—Cepheid received emergency use authorization from the FDA for its Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses that cause COVID-19, flu A, flu B, and RSV infections from a single patient sample.

FDA clears Simplexa flu A/B, RSV assay

November 2020—DiaSorin Molecular received FDA clearance for its Simplexa Flu A/B & RSV Direct Gen II kit. The assay can be run alone or alongside the Simplexa COVID-19 Direct kit, allowing for differential diagnosis of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus.

ARUP shares formula for transport media

November 2020—ARUP Laboratories’ formula for ARUP Transport Media is now available to other laboratories. The formula is provided at the end of an article about an ARUP and University of Utah Health study in which the transport media was used for specimen collection (Hanson KE, et al. J Clin Microbiol. Accepted manuscript. Published online Aug. 12, 2020. doi:10.1128/JCM.01824-20).

Bio-Rad controls for COVID-19 testing

November 2020—Bio-Rad Laboratories launched its in vitro diagnostics Virotrol SARS-CoV-2 and Viroclear SARS-CoV-2 positive and negative quality controls for use in antibody testing of SARS-CoV-2. The serological controls are available for in vitro assay procedures in the U.S. and are CE marked for IVD markets outside the U.S.

MARKETPLACE

TRENDING